Cargando…

Red Blood Cell Metabolism in Pyruvate Kinase Deficient Patients

Background: Pyruvate kinase deficiency (PKD) is the most frequent congenital enzymatic defect of glycolysis, and one of the most common causes of hereditary non spherocytic hemolytic anemia. Therapeutic interventions are limited, in part because of the incomplete understanding of the molecular mecha...

Descripción completa

Detalles Bibliográficos
Autores principales: Roy, Micaela K., Cendali, Francesca, Ooyama, Gabrielle, Gamboni, Fabia, Morton, Holmes, D’Alessandro, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567077/
https://www.ncbi.nlm.nih.gov/pubmed/34744776
http://dx.doi.org/10.3389/fphys.2021.735543
_version_ 1784594157689372672
author Roy, Micaela K.
Cendali, Francesca
Ooyama, Gabrielle
Gamboni, Fabia
Morton, Holmes
D’Alessandro, Angelo
author_facet Roy, Micaela K.
Cendali, Francesca
Ooyama, Gabrielle
Gamboni, Fabia
Morton, Holmes
D’Alessandro, Angelo
author_sort Roy, Micaela K.
collection PubMed
description Background: Pyruvate kinase deficiency (PKD) is the most frequent congenital enzymatic defect of glycolysis, and one of the most common causes of hereditary non spherocytic hemolytic anemia. Therapeutic interventions are limited, in part because of the incomplete understanding of the molecular mechanisms that compensate for the metabolic defect. Methods: Mass spectrometry-based metabolomics analyses were performed on red blood cells (RBCs) from healthy controls (n=10) and PKD patients (n=5). Results: In PKD patients, decreases in late glycolysis were accompanied by accumulation of pentose phosphate pathway (PPP) metabolites, as a function of oxidant stress to purines (increased breakdown and deamination). Markers of oxidant stress included increased levels of sulfur-containing compounds (methionine and taurine), polyamines (spermidine and spermine). Markers of hypoxia such as succinate, sphingosine 1-phosphate (S1P), and hypoxanthine were all elevated in PKD subjects. Membrane lipid oxidation and remodeling was observed in RBCs from PKD patients, as determined by increases in the levels of free (poly-/highly-unsaturated) fatty acids and acyl-carnitines. Conclusion: In conclusion, in the present study, we provide the first overview of RBC metabolism in patients with PKD. Though limited in scope, the study addresses the need for basic science to investigate pathologies targeting underrepresented minorities (Amish population in this study), with the ultimate goal to target treatments to health disparities.
format Online
Article
Text
id pubmed-8567077
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85670772021-11-05 Red Blood Cell Metabolism in Pyruvate Kinase Deficient Patients Roy, Micaela K. Cendali, Francesca Ooyama, Gabrielle Gamboni, Fabia Morton, Holmes D’Alessandro, Angelo Front Physiol Physiology Background: Pyruvate kinase deficiency (PKD) is the most frequent congenital enzymatic defect of glycolysis, and one of the most common causes of hereditary non spherocytic hemolytic anemia. Therapeutic interventions are limited, in part because of the incomplete understanding of the molecular mechanisms that compensate for the metabolic defect. Methods: Mass spectrometry-based metabolomics analyses were performed on red blood cells (RBCs) from healthy controls (n=10) and PKD patients (n=5). Results: In PKD patients, decreases in late glycolysis were accompanied by accumulation of pentose phosphate pathway (PPP) metabolites, as a function of oxidant stress to purines (increased breakdown and deamination). Markers of oxidant stress included increased levels of sulfur-containing compounds (methionine and taurine), polyamines (spermidine and spermine). Markers of hypoxia such as succinate, sphingosine 1-phosphate (S1P), and hypoxanthine were all elevated in PKD subjects. Membrane lipid oxidation and remodeling was observed in RBCs from PKD patients, as determined by increases in the levels of free (poly-/highly-unsaturated) fatty acids and acyl-carnitines. Conclusion: In conclusion, in the present study, we provide the first overview of RBC metabolism in patients with PKD. Though limited in scope, the study addresses the need for basic science to investigate pathologies targeting underrepresented minorities (Amish population in this study), with the ultimate goal to target treatments to health disparities. Frontiers Media S.A. 2021-10-21 /pmc/articles/PMC8567077/ /pubmed/34744776 http://dx.doi.org/10.3389/fphys.2021.735543 Text en Copyright © 2021 Roy, Cendali, Ooyama, Gamboni, Morton and D’Alessandro. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Roy, Micaela K.
Cendali, Francesca
Ooyama, Gabrielle
Gamboni, Fabia
Morton, Holmes
D’Alessandro, Angelo
Red Blood Cell Metabolism in Pyruvate Kinase Deficient Patients
title Red Blood Cell Metabolism in Pyruvate Kinase Deficient Patients
title_full Red Blood Cell Metabolism in Pyruvate Kinase Deficient Patients
title_fullStr Red Blood Cell Metabolism in Pyruvate Kinase Deficient Patients
title_full_unstemmed Red Blood Cell Metabolism in Pyruvate Kinase Deficient Patients
title_short Red Blood Cell Metabolism in Pyruvate Kinase Deficient Patients
title_sort red blood cell metabolism in pyruvate kinase deficient patients
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567077/
https://www.ncbi.nlm.nih.gov/pubmed/34744776
http://dx.doi.org/10.3389/fphys.2021.735543
work_keys_str_mv AT roymicaelak redbloodcellmetabolisminpyruvatekinasedeficientpatients
AT cendalifrancesca redbloodcellmetabolisminpyruvatekinasedeficientpatients
AT ooyamagabrielle redbloodcellmetabolisminpyruvatekinasedeficientpatients
AT gambonifabia redbloodcellmetabolisminpyruvatekinasedeficientpatients
AT mortonholmes redbloodcellmetabolisminpyruvatekinasedeficientpatients
AT dalessandroangelo redbloodcellmetabolisminpyruvatekinasedeficientpatients